The study aims to evaluate the efficacy, safety, and tolerability of IMVT-1402 compared to placebo in reducing the risk of Relapse in adult participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Specifically, it seeks to determine if IMVT-1402 can maintain disease control better than placebo when transitioned from standard of care therapies (immunoglobulin or corticosteroids).

The study is for adult patients with a clinical diagnosis of CIDP who currently receive chronic, stable doses of systemic corticosteroids or immunoglobulin therapy for the treatment of CIDP.

​

To qualify, participants generally must:

​

• Must be adult participants (18 years of age or older).

​

• Have met clinical diagnostic criteria for typical CIDP or one of the specified variants (multifocal CIDP or motor CIDP) per the EAN/PNS guideline.

​

• Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNS guideline.

​

• Must have been receiving chronic, stable doses of systemic corticosteroids, or immunoglobulin therapy for at least 3 months for the treatment of CIDP at the time of the Screening Visit.

​

• Have evidence to suggest an underlying active disease process even if symptoms are well controlled at Screening, with documented improvement after starting a first-line therapy or deterioration after reduction/missed dose of a first-line therapy within 36 months of Screening.